Scynexis to price IPO of 4,230,800 shares between $12.00 and $14.00

Offering conducted by RBC Capital, Canaccord Genuity, JMP Securities

By Devika Patel

Knoxville, Tenn., March 24 - Scynexis, Inc. said it will sell 4,230,800 common shares in its initial public sale with a 30-day greenshoe of 634,620 additional shares.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

RBC Capital Markets and Canaccord Genuity are the joint bookrunners. JMP Securities is the lead manager.

The drug discovery and development company is based in Research Triangle Park, N.C. It has applied to list its shares on the Nasdaq under the symbol "SCYX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.